Human Platelet Lysate Market Size, Share & Industry Analysis, By Type (Heparin-based Human Platelet Lysate, Heparin-free Human Platelet Lysate, Others (Fibrinogen Depleted, etc.)), By Application (Research, Therapeutic), By End-User (Pharmaceutical and biotechnology companies, Academic & Research Institutes, Others)and Regional Forecast, 2024-2032

Human platelet lysate (HPL) is a cell culture growth supplement derived from the human donor platelets after thawing and freezing. HPL products are standardized and safe cell culture supplements that ensure high cell performance and reproducible results. They contain abundant platelet-derived growth factors and cytokines, which stimulate cellular proliferation to maintain differential potential. It also serves as an alternative to Fetal Bovine Serum (FBL) in cell and tissue culture. Increased applications of human platelet lysate in cell culture, rising acceptance of HPL due to its various advantages, growing opposition of animal-derived blood products, an increased number of mergers and acquisitions among key players to expand their product portfolio in HPL are some of the factors that are expected to fuel the growth of market during the forecast period. For instance, in May 2018, PL BioScience GmbH and Biogelx collaborated intending to enhance their current human platelet lysate based nutrient matrix and expand the range of PL Bioscience’s stem cell platform.

Rising application of human platelet lysates in cell culture, growing investment in research and development of human platelet lysates, and increased number of mergers and acquisitions among key players to expand their product portfolio in HPL are some of the factors that are driving the market growth.

However, high costs and increased risk of transmission of infectious communicable diseases are likely to decline the growth of the human platelet lysate market.

Market Segmentation:

By type, the market can be segmented into heparin-based human platelet lysate, heparin-free human platelet lysate, and others (fibrinogen depleted, etc.). By application, the market can be segmented into research and therapeutic. By end-users, the market can be segmented into pharmaceutical and biotechnology companies, academic & research institutes, and others.

Geographically, the human platelet lysate market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Key Players Covered:

The major companies in the global human platelet lysate market report include Merck KGaA, Compass Biomedical, Inc., STEMCELL Technologies Inc., Regenexx, Life Science Group Ltd, Macopharma, BBI Solutions, COOK, and other prominent players.

Key Insights

• Regulatory Scenario (Key Countries/ Region)


• Epidemiology Overview: Key Disease Indications (Key Countries/ Regions)


• Recent Industry Developments such as mergers, acquisitions, and partnerships

Regional Analysis:

The global human platelet lysate market is expected to be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to lead the global human platelet lysate market due to the rising application of human platelet lysate in cell culture and growing research and development activities in human platelet lysate coupled with favourable support from the regulatory authorities. Europe is expected to have second-largest market share during the forecast period owing to the rising acceptance of HPL due to its various advantages and improved healthcare facilities. Asia Pacific is expected to witness growth with the highest CAGR during the forecast period due to the increasing opposition of animal-derived blood products and growing awareness about the human platelet lysate. On the other hand, Latin America and the Middle East and Africa is projected to have a lucrative growth in the human platelet lysate market in the upcoming years owing to the rising demand for advanced healthcare facilities.

Segmentation

Human Platelet Lysate Industry Developments

• In May 2018, PL BioScience GmbH and Biogelx collaborated with an aim to enhance their current human platelet lysate based nutrient matrix and expand the range of PL Bioscience’s stem cell platform.


• In March 2017, Biological Industries USA entered into a distribution agreement with Mill Creek Life Sciences with an aim to add PLTMax human platelet lysate to its growing stem cell portfolio.